Efficacy of continuous positive airway pressure therapy upon resistant hypertension in patients with obstructive sleep apnea hypopnea syndrome

National Medical Journal of China

Volumn 89, Issue 26, 2009, Pages 1811-1814

  Zhang, Xi Long ^a   Li, Yan Qun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Aldosterone; Continuous positive airway pressure; Hypertension; Sleep apnea,obstructive

Indexed keywords

ADULT; ARTICLE; FEMALE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; OBESITY HYPOVENTILATION SYNDROME; POSITIVE END EXPIRATORY PRESSURE; SLEEP APNEA SYNDROME;

ADULT; CONTINUOUS POSITIVE AIRWAY PRESSURE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OBESITY HYPOVENTILATION SYNDROME; SLEEP APNEA, OBSTRUCTIVE;

EID: 84871343633     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2009.26.006     Document Type: Article

References (17)

1. Phillips CL, Cistulli PA. Obstructive sleep apnea and Hypertension: epidemiology, mechanisms and treatment effects. Minerva Med, 2006, 97: 299-312.
2. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Assocation Council for High Blood Pressure Research Professional Education Committee, Councial on Clinical Cardiology, Stroke Council, and council on Cardiovascular Nursing. J Am Coll Cardiol, 2008, 52: 686-717.
3. 2006, 26: 1494-1496.
4. Gonçalves SC, Martinez D, Gus M, et al. Obstructive sleep apnoea and resistant hypertension: a case-control study. Chest, 2007, 132: 1858-1862.
5. Campos-Rodriguez F. Screening for sleep apnea in patients with resistant hypertension. Am J Hypertens, 2008, 21: 728.
6. Pimenta E, Calhoun DA, Oparil S. Sleep apnea, aldosterone, and resistant hypertension. Prog Cardiovasc Dis, 2009, 51: 371-380.
7. Logan AG, Tkakova R, Perlikowski SM, et al. Refractory hypertension and sleep apnoea: effect of CPAP on blood pressure and baroreflex. Eur Respir J, 2003, 21: 241-247.
8. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet, 2003, 362: 1527-1535.
9. 2002, 25: 195-198.
10. 2005, 13: 2-36.
11. Pimenta E, Gaddam KK, Oparil S. Mechanisms and treatment of resistant hypertension. J Clin Hypertens (Greenwich), 2008, 10: 239-244.
12. Calhoun DA, Nishizaka MK, Zaman MA, et al. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest, 2004, 125: 112-117.
13. Saarelainen S, Hasan J, Siitonen S, et al. Effect of nasal CPAP treatment on plasma volume, aldosterone and 24-h blood pressure in obstructive sleep apnoea. J Sleep Res, 1996, 5: 181-185.
14. Maillard D, Fineyre F, Dreyfuss D, et al. Pressure-heart rate responses to alpha-adrenergic stimulation and hormonal regulation in normotensive patients with obstructive sleep apnea. Am J Hypertens, 1997, 10: 24-31.
15. Follenius M, Krieger J, Krauth MO, et al. Obstructive sleep apnea treatment: peripheral and central effects on plasma renin activity and aldosterone. Sleep, 1991, 14: 211-217.
16. Duprez DA. Aldosterone and the vasculature: mechanisms mediating resistant hypertension. J Clin Hypertens (Greenwich), 2007, 9(1 Suppl 1): 13-18.
17. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, et al. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest, 2007, 131: 453-459.